Sectors

ICLR
ICON Public Limited Company
118.01
2 x 84.71
2 x 149.38
bid
ask
+
0.92
0.78%
10:12 AM
timesize
Ytd -35.24%
1y -9.68%
115.56
day range
118.58
66.57
52 week range
211.00
Open 117.27 Prev Close 117.09 Low 115.56 High 118.58 Mkt Cap 9.18B
Vol 99.16K Avg Vol 1.31M EPS 7.42 P/E 15.91 Forward P/E 10.24
Beta 1.23 Short Ratio 2.02 Inst. Own 106.45% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 05-20 50-d Avg 109.61 200-d Avg 154.06 1yr Est 137.21
Earning
Date For Estimate Reported Surprise surprise %
2026-05-13 2026-03 2.95 N/A N/A N/A
2026-04-01 2025-12 3.3 N/A N/A N/A
2025-10-22 2025-09 3.28 3.31 0.03 0.91%
2025-07-23 2025-06 3.18 3.26 0.08 2.52%
2025-04-30 2025-03 3.08 3.19 0.11 3.57%
2025-02-19 2024-12 3.42 3.43 0.01 0.29%
Upgrade / Downgrade
Date Firm Action From To
2026-03-26 BMO Capital Upgrade Market Perform Outperform
2026-03-11 Citigroup Upgrade Neutral Neutral
2026-03-09 Barclays Upgrade Equal-Weight Equal-Weight
2026-02-23 Jefferies Upgrade Hold Buy
2026-02-18 TD Cowen Upgrade Hold Buy
2026-01-22 TD Cowen Upgrade Hold Hold
Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Artisan Partners Limited Partnership 8.28M 969.38M 10.25%
2025-12-30 Wellington Management Group, LLP 4.35M 509.43M 5.39%
2025-12-30 Orbis Allan Gray Ltd 4.21M 493.49M 5.22%
2026-03-30 Invesco Ltd. 3.88M 454.18M 4.80%
2026-03-30 Principal Financial Group, Inc. 3.31M 387.78M 4.10%
2025-12-30 FMR, LLC 3.10M 362.73M 3.84%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 Artisan Partners Funds Inc.-Artisan International Value Fund 5.17M 605.36M 6.40%
2026-01-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 1.21M 142.14M 1.50%
2025-12-30 HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund 1.05M 122.83M 1.30%
2026-01-30 VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund 999.22K 117.00M 1.24%
2026-01-30 AIM Sector Funds (Invesco Sector Funds)-INVESCO SMALL CAP VALUE FUND 975.20K 114.19M 1.21%
2026-01-30 Principal Funds, Inc-International Equity Fund 971.39K 113.74M 1.20%
Split
Split Date
2 : 1 2008-08-13
2 : 1 2006-10-24